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Background: NCIC CTG BR.21 is a landmark trial, establishing the 
epidermal growth factor receptor inhibitor erlotinib, as a second or 
third line treatment option for advanced NSCLC after failure of cispla-
tin based chemotherapy. Overall survival and quality of life outcomes 
were superior in the erlotinib arm compared to best supportive care, 
with an overall survival of 6.7 vs. 4.7 months (p<0.001). In view of this 
clinical beneﬁt, the cost effectiveness of erlotinib was investigated. 
Methods: Direct medical resource utilization data were collected 
from the BR.21 trial database. The analysis was performed based on 
Canadian Public Healthcare System perspective, using costs (CAD$ 
2006) from provincial sources. Direct medical costs include: drug, hos-
pitalizations; toxicity, procedures, transfusions and radiation therapy. 
Non-medical and indirect costs were not included. Average costs per 
treatment arm are calculated. 
Results: Utilization data were collected on 731 patients (100%), of 
which 488 patients were assigned to the erlotinib arm. Preliminary 
results show, an overall mean cost of erlotinib alone, per patient, is 
$10,584 and $11,642 with additional mark up fees. 
Conclusion: The predominant cost in the erlotinib arm is related to 
drug cost, but this may be within an acceptable level of health care 
expenditure. Cost effectiveness and costing in patient subgroups will be 
presented. 
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IFCT0401 trial: Phase II study of gefitinib administered as 
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Background: ADC-BACs are distinguished from other ADCs by 
epidemiological, clinical and CT scan presentations as well as mo-
lecular biology, leading to some responses to EGF-TKI. We therefore 
conducted a prospective, multicentric, phase II trial to evaluate geﬁtinib 
(250 mg/d) as ﬁrst-line treatment in non-resectable ADC-BAC. 
Methods: Inclusion criteria were previously untreated, non-resectable 
cyto/pathologically proven ADC-BAC. Primary objective was disease 
control rate (DCR) at 3 months. Secondary exploratory objectives were 
progression free survival (PFS), overall survival (OS), and identiﬁca-
tion of factors associated with PFS and OS using multivariate cox 
model analyses. 
Results: From 04/04 to 06/05, 88/90 enrolled patients were eligible. All 
were caucasians with stage IV disease, PS <2 in 81.8%, age >70 yrs in 
36.4%, females in 54.4% and non-smokers in 43.2%. DC was achieved 
in 25/85 evaluable patients (DCR=29.3%, CI=[20-39]). Median PFS 
was 2.9 months (CI=[2.4-3.2]) and median survival 13.3 months 
(CI=[10.1-21.8]), with a 1-year survival of 55.7% (CI=[44.4-65.5]). DC 
was independently associated with age >70 yrs (OR=4.9, p=.047); nev-
er-smoking (OR=8.1, p=.015); Respiratory Symptoms Scale (RSS) <9 
(OR=18.7, p=.002); non-mucinous BAC (OR=15.1, p=.006) and rash 
(OR=2.1, p=.02). When DC at 3 months was not included as factor in 
the cox model, reduced risk of progression was independently associ-
ated with RSS <9 (HR=0.512, p=.03); non-mucinous BAC (HR=0.316, 
p=.01) and presence of rash (HR=0.440, p=.004). However, when DC 
was included in the model, reduced risk of progression was strongly 
associated with DCR (HR=0.025, p<.0001) with independent effect 
of non-mucinous BAC histology (HR=0.380, p=.04). When DC was 
not included as factor in the cox model, decreased risk for death was 
independently associated with initial stage I-IIIa (HR=0.213, p=.01); 
absence of bronchorrhea and oxygen support (HR=0.056, p=.01 and 
HR=0.349, p=.007); RSS <9 (HR=0.363, p=.003); and presence of rash 
(HR=0.338, p=.0007). However, DC at 3 months did not affect the risk 
for OS when included in the Cox model. 
Conclusions: Geﬁtinib seems active as ﬁrst-line treatment of non-
resectable ADC-BAC especially, in older patients, never-smokers, 
patients with fewer pulmonary symptoms and with non-mucinous BAC 
subtype. While DC by geﬁtinib at 3 months strongly predicted PFS, 
it did not independently inﬂuenced survival in the IFCT0401 popula-
tion. This suggested that ADC-BAC has been controlled by second-line 
chemotherapy given after progression under geﬁtinib in some patients 
of the IFCT0401 cohort. 
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Concordance of the determination of EGFR and K-ras mutations 
in a tumor bank obtained by 15 centers in france: a pilot study of 
the ERMETIC project.
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Background: Epidermal Growth Factor - Tyrosine Kinase Inhibitors 
(EGFR-TKIs) and especially erlotinib, are authorized in Europe for 
the treatment of metastatic non-small cell lung cancer (NSCLC) after 
failure of, at least one, prior chemotherapy. Although, it has been sug-
gested that biological markers (EGFR over-expression, EGFR gene 
polysomy/ampliﬁcation and EGFR and K-ras mutations) are predictive 
of efﬁcacy of EGFR-TKIs, they are not used in clinical practice. In 
order to help implementation of these biomarkers in France, the French 
